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Cbx3/HP1γ deficiency confers 
enhanced tumor-killing capacity on 
CD8+ T cells
Michael Sun1,*, Ngoc Ha1,2,*, Duc-Hung Pham1,3, Megan Frederick4, Bandana Sharma5, 
Chie Naruse6, Masahide Asano6, Matthew E. Pipkin4, Rani E. George5,7 & To-Ha Thai1
Cbx3/HP1γ is a histone reader whose function in the immune system is not completely understood. 
Here, we demonstrate that in CD8+ T cells, Cbx3/HP1γ insufficiency leads to chromatin remodeling 
accompanied by enhanced Prf1, Gzmb and Ifng expression. In tumors obtained from Cbx3/HP1γ-
insufficient mice or wild type mice treated with Cbx3/HP1γ-insufficient CD8+ T cells, there is an increase 
of CD8+ effector T cells expressing the stimulatory receptor Klrk1/NKG2D, a decrease in CD4+ CD25+ 
FOXP3+ regulatory T cells (Treg cells) as well as CD25+ CD4+ T cells expressing the inhibitory receptor 
CTLA4. Together these changes in the tumor immune environment may have mitigated tumor burden 
in Cbx3/HP1γ-insufficient mice or wild type mice treated with Cbx3/HP1γ-insufficient CD8+ T cells. 
These findings suggest that targeting Cbx3/HP1γ can represent a rational therapeutic approach to 
control growth of solid tumors.
The heterochromatin protein 1 (HP1) family of proteins are histone readers that associate with modified his-
tones, and are involved in epigenetic regulations1,2. Cbx3/HP1γ interacts with the methyl groups of histone H3 at 
lysine 9 (H3K9Me3) and with methyl transferases as well as other proteins3–6. It has been shown to associate with 
both heterochromatin and euchromatin suggesting it may participate in transcriptional repression and activa-
tion, respectively7,8. Additionally, Cbx3/HP1γ controls gene expression through two intimately related processes: 
transcriptional elongation and co-transcriptional splicing of nascent RNA transcripts9–12. Homozygous germline 
deletion of Cbx3/HP1γ in mice causes embryonic lethality13,14. Previously we have shown that Cbx3/HP1γ haplo-
insufficiency is sufficient to regulate the high-affinity antibody response to protein antigens15. However, it has not 
been determined how Cbx3/HP1γ does so.
After encountering infected or malignant cells, naïve CD8+ T cells become activated and differentiate into 
effector cells to clear the infectious agent or control tumor growth16. Majority of effector cells die, but a small 
number will become memory cells. However, under persistent antigen exposure as in cancer or chronic infec-
tions, a subset of CD8+ effector T cells can enter an altered differentiation program known as T-cell exhaus-
tion (TEX)17. CD8+ TEX cells express unique transcription factors as well as those shared with effector/memory 
cells, among them are Tbx21/T-bet, Eomesodermin (Eomes) and Prdm1/Blimp-1. However, these factors interact 
with distinct partners in addition to being differentially expressed in the two populations17,18. More importantly, 
CD8+ TEX cells can be reversed to become functional. Thus, identifying novel mechanisms that can reinvigorate 
exhausted CD8+ T cells would provide means to control tumor growth.
The ability of CD8+ effector T cells to kill targets requires the production of lytic molecules, perforin (encoded 
by Pfr1) and granzyme B (encoded by Gzmb), and the inflammatory cytokine interferon γ (INFγ , encoded by 
Ifng). Induction of Pfr1, Gzmb and Ifng is regulated in part by the transcription factor Runt-related 3 (Runx3)19,20.
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Cytotoxic CD8+ T cells detect malignant-self either directly through interaction of the T-cell receptor (TCR) 
on CD8+ T cells with tumor antigens or indirectly in the form of so-called “danger signals” such as the reti-
noic acid early transcript-1 (RAE-1) and related ligands. Nonetheless, most activated cytotoxic CD8+ T cells 
(human and mouse) share the expression of the natural killer group 2, member D receptor (NKG2D) encoded by 
Klrk1, which upon binding to RAE-1 or related ligands, induced on tumor cells, stimulates effector responses that 
are independent of TCR21. For many tumors, tumor infiltrating Klrk1/NKG2D+ CD3+ CD8+ T cells or T cells 
expressing chimeric Klrk1/NKG2D receptor were shown to have promising anti-tumor efficacy22–27.
The elimination of CD4+ FOXP3+ Treg cells by T cells expressing the chimeric Klrk1/NKG2D receptor in the 
ovarian tumor microenvironment inhibited tumor growth and increased survival in mice27. Similarly, treatment 
of melanoma tumor-bearing mice with monoclonal antibody specific for CTLA4 led to the selective depletion of 
CD4+ Treg cells and a concomitant increase of CD8+ effector T cells within tumor lesions resulting in increased 
survival28,29. These results suggest that finding new means to manipulate the ratio of effector CD8+ T cells over 
CD4+ Treg cells is a viable strategy to control cancer.
Neuroblastoma (NB) is the most common extracranial solid tumor of childhood and the third most common 
cause of pediatric cancer death30. Despite the use of multimodal therapy, patients with high-risk NB have a poor 
prognosis due to high rate of relapse. Treatment with anti-GD2, a ganglioside expressed on a subset of NB tumors 
cells, is the current standard of care for high-risk NB31–33. However, this therapy causes severe pain requiring the 
use of continuous opiate infusions because GD2 is also expressed on pain fibers, and not all patients respond 
to this therapy34. Therefore, there is a need to explore novel approaches including immunotherapies to control 
high-risk NB.
Here we find that adoptive transfer of Cbx3/HP1γ -insufficient CD8+ effector T cells alone into wt 
tumor-bearing mice greatly limits tumor growth. Within the tumor microenvironment of Cbx3/HP1γ -insufficient 
mice or wt mice treated with Cbx3/HP1γ -insufficient CD8+ T cells, we detect an increase of Klrk1/NKG2D+ infil-
trating CD8+ effector T cells, a concomitant decrease in CD4+ Treg cells. We propose that together these changes 
may have provided the anti-tumor immunity observed in mice.
Results
Cbx3/HP1γ-insufficient CD8+ T cells are endowed with enhanced effector capacity. Recently, 
we showed that in C57BL/6 mice, haploinsufficiency of Cbx3/HP1γ impairs the lymphoid-tissue germinal center 
(GC) reaction and high-affinity antibody response against a thymus (T)-dependent antigen (Ag) conjugated to 
chicken gamma globulin (NP-CGG)15. The effects were CD8+ -T-cell-intrinsic. Additionally, Cbx3/HP1γ protein 
was induced in CD8+ T cells after activation, and its level was greatly reduced in insufficient cells (Fig. S1A). 
These results prompted us to ask what CD8+ T-cell functions are controlled by Cbx3/HP1γ and by what mech-
anisms. Quantitative polymerase chain reaction (qPCR) and Western blot analyses demonstrated that on day 2 
after activation, Cbx3/HP1γ -insufficient CD8+ T cells expressed more Bcl6, Prdm1 and Tbx21 compared to con-
trol cells (Fig. 1A,B). On day 5 of activation, Prdm-1 expression was sustained at a high level in Cbx3/HP1γ -insuf-
ficient CD8+ T cells while that of Runx3 and Bcl6 was unaltered (Fig. 1A). By contrast, Eomes expression was 
repressed in Cbx3/HP1γ -insufficient CD8+ T cells on both days compared to control cells (Fig. 1A,B). Expression 
of Prf1, Gzmb and Ifng was upregulated in Cbx3/HP1γ -insufficient CD8+ T cells compared to controls (∼ 1.5 fold, 
2 fold and 1.5 fold increase, respectively) (Fig. 1C–E). Correspondingly, a higher percentage of IFNγ + cells was 
detected in Cbx3/HP1γ -insufficient cultures (50%) compared to wt controls (22%), and insufficient CD8+ T cells 
also produced a higher amount of IFNγ protein (Fig. 1D). A phenotypic survey of wt and insufficient activated 
CD8+ T cells showed they expressed similar levels of IL-2, CD25, CD127 (IL-7Rα ) and CD132 (common γ chain 
or IL-2Rγ ) (Fig. S1B–D). Similar frequency of effector (CD44hiCD62Llo) and central (CD44hiCD62Lhi) memory 
CD8+ T cells was detected in wt and Cbx3/HP1γ -insufficient mice suggesting that activation did not appear to 
favor the expansion or reduction of either population in Cbx3/HP1γ -insufficient mice (Fig. S1E,F). To determine 
if the augmented production of perforin, granzyme B and IFNγ would endow Cbx3/HP1γ -insufficient CD8+ T 
cells to better induce apoptosis than wt cells, in vitro-activated CD8+ and CD4+ T cells were co-cultured with 
target neuroblastoma NB-9464 tumor cells35, and tumor-cell apoptosis assessed by measuring cleaved/activated 
caspase 3 (CC3) production. At a ratio of 5:1 (5 effector cells to 1 target cell) more CC3 was detected in tumor cells 
co-cultured with Cbx3/HP1γ -insufficient CD8+ effector T cells compared to control co-cultures (Fig. 1F). Wild 
type and insufficient CD4+ activated T cells induced similar CC3 level. These results show that after activation, 
Cbx3/HP1γ -insufficient CD8+ T cells could differentiate into effector cells armed with enhanced killing capacity 
to induce apoptosis in tumor cells.
Cbx3/HP1γ deficiency limits tumor growth in mice. CD8+ effector T cells can directly kill tumor cells 
by releasing perforin, granzyme B and IFNγ . We reasoned that Cbx3/HP1γ -insufficient CD8+ T cells armed with 
heightened killing capacity would be more efficient in controlling tumor growth compared to wt cells. To exclude 
the contribution of non-immune cells in tumor killing, we performed fetal liver reconstitution of Rag2−/−cγ−/− 
mice, which have no T, B, NKT or NK cells. At week 10, mice reconstituted with wt littermate, Cbx3/HP1γ +/− or 
Cbx3/HP1γ −/− E17.5 fetal livers were implanted subcutaneously (sc) with NB-9464 tumor cells. Tumor growth 
was visible in mice reconstituted with wt fetal livers compared to those receiving Cbx3/HP1γ +/− or Cbx3/HP1γ −/− 
fetal livers (Fig. 2A). Concordantly, tumor volume was reduced in mice reconstituted with Cbx3/HP1γ +/− or 
Cbx3/HP1γ −/− fetal livers compared to those receiving wt fetal livers (Fig. 2B). As expected, CD8+ T cells from 
Cbx3/HP1γ +/− and Cbx3/HP1γ −/− fetal liver chimeras expressed significantly less and no Cbx3/HP1γ , respec-
tively (Fig. 2B). To confirm that tumor volume reduction occurred in our Cbx3/HP1γ -insufficient mice as well, 
NB-9464 tumor cells were implanted in wt and Cbx3/HP1γ -insufficient mice. At day 30 after implantation, tum-
ors from Cbx3/HP1γ -insufficient mice were smaller than those from wt mice, and ∼ 50% of tumor-bearing wt 
mice suffered tumor invasion into their peritoneal cavity, which was not observed in Cbx3/HP1γ -insufficient 
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Figure 1. Cbx3/HP1γ-insufficient CD8+ effector T cells are endowed with enhanced killing capacity.  
(A) Bcl6, Prdm1/Blimp, Runx3, Eomes and Tbx21 mRNA levels were assessed by RT-qPCR from in vitro-activated 
CD8+ T cells; p = 0.05 for Eomes day 5. (B) Eomes and T-bet proteins were detected by Western blots using total 
lysates from cells generated as in (A); lo: low rIL-2 concentration (10 U/ml), hi: high IL-2 (100 U/ml.  
(C) Gzmb, Ifng and Prf1 mRNA levels were determined by RT-qPCR using cells as in (A). (D) The frequency 
of IFNγ + population was determined using intracellular FACS with cells as in (A). Numbers in FACS plots 
represented percent cells. Histograms indicated IFNγ protein expression levels. (E) Granzyme B protein expression 
was detected by Western blots using cells as in (A). (F) Effector CD4+ and CD8+ T cells were co-cultured with 
target NB-9464 cells at a 1:1 or 5:1 effector to target ratio for 24 hrs. Apoptosis, indicated by the presence of cleaved 
caspase 3, was assessed with Western blots using total NB-9464 cell lysates from co-cultures. All results were 
representative of 3–5 independent experiments. For (A and C), results represented fold difference; unit 1 indicated 
no change (n = 10 of each genotype). Full-length Western blots are shown in Supplementary Information. For A 
and C, statistical analysis was performed with GrathPad unpaired student t-test.
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Figure 2. Cbx3/HP1γ deficiency limits tumor growth in mice. (A) Fetal liver reconstitution was performed with 
fetal liver cells from wt littermate, Cbx3/HP1γ +/− and Cbx3/HP1γ −/− day 17.5 embryos (E17.5) into Rag2−/−cγ−/− 
recipient mice (n = 5-6 recipients for each genotype). Ten weeks after reconstitution, chimeric mice were implanted 
subcutaneously (sc) with NB-9464 tumor cells. Red arrows indicated tumors. (B) Tumor volume was measured on 
day 21 and every 2 days until day 29. Total Cbx3/HP1γ protein expression was assessed in day 5 in vitro-generated 
CD8+ effector T cells from chimeric mice. (C) Tumor implantation in wt and Cbx3/HP1γ -insufficient mice was 
performed as in (A). Red arrows and red outlines indicated tumor size and tumor in the peritoneal cavity of wt mice; 
n = 8 for each genotype. (D) Tumor volume was measured. (E) Tumor morphology and lymphocyte infiltration 
was assessed by hematoxylin and eosin (H&E) stain on paraffin sections of day 30 tumors. L = lymphocyte, 
T = tumor cells, red outlines indicated lymphocyte regions. (F) KI-67 was detected by immunohistochemistry on 
paraffin sections of day 30 tumors. Brown stain indicated KI-67 positivity, white unstained areas showed necrosis. 
For (E and F), images were shown as 100X (left, 10X ocular and 10X objective lens) and 400X (right, 10X ocular 
and 40X objective lens); 25 μ m scale bar. (G) Day 30 tumors were excised and tumor cells were lysed. Cleaved 
caspase 3 was detected by Western blots. (H) RAE-1 protein expression was determined by Western blots in total 
lysates of day 30 tumors excised from wt and Cbx3/HP1γ -insufficient mice. (I) Relative Pd-l1 mRNA expression 
was measured by RT-qPCR using day 30 tumor cells. All results were representative of 3 independent experiments 
with 4 different tumors. Full-length Western blots are shown in Supplementary Information. Statistical analysis was 
performed with the Graphpad Two-Way Anova (B and D) and student t-test (I).
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mice (Fig. 2C). Median volume of day 30 tumors from Cbx3/HP1γ -insufficient mice was 2.4 fold lower than 
that of wt mice (Fig. 2D). NB-9464 tumor-bearing Cbx3/HP1γ -insufficient mice survived longer than controls 
(Fig. S2). Tumors from Cbx3/HP1γ -insufficient mice exhibited extensive lymphocytic infiltration, decreased 
tumor-cell proliferation (less KI-67+ tumor cells) as well as large areas of necrosis, and increased tumor-cell apop-
tosis (higher levels of CC3) (Fig. 2E–G). By contrast, tumors excised from wt or Cbx3/HP1γ -insufficient mice 
expressed similar levels of the stimulatory RAE-1 and inhibitory programmed cell death ligand 1 (PD-L1) ligands, 
both of which were induced in tumor cells (Fig. 2H,I). These results demonstrate that Cbx3/HP1γ -insufficient 
mice are as efficient in controlling tumor growth as Cbx3/HP1γ −/− fetal liver chimeras.
Cbx3/HP1γ insufficiency increases CD8+ effector T cells and reduces CD4+ Treg cells in tumor 
microenvironment. The successful control of tumor is in part dictated by the simultaneous activation of 
immune cells including CD8+ effector T cells and the elimination of immune suppressive elements in the tumor 
microenvironment. Within the microenvironment of NB-9464 tumors from Cbx3/HP1γ -insufficient mice, we 
detected an increased frequency of CD122+ CD44+ CD8+ (2.8 fold higher) T cells expressing the stimulatory 
receptor Klrk1/NKG2D (2.5-fold higher; Fig. 3A,B). The frequency of CD122+ IFNγ + T cells among the CD8+ 
NKG2D+ population was 5 fold higher in tumors from Cbx3/HP1γ -insufficient mice compared to wt mice 
Figure 3. Cbx3/HP1γ insufficiency increases CD8+ effector T cells and reduces CD4+ Treg cells in tumor 
microenvironment. Flow cytometry was performed to identify tumor-infiltrating lymphocyte populations 
within day 30 tumors excised from wt and Cbx3/HP1γ -insufficient mice (n = 8). Graphs compiled FACS data. 
(A) NK1.1−CD122+ CD44+ CD3+ CD8+ T cells were gated from total CD8+ T-cell population in day 30 tumor-
cell suspensions. Percent NK1.1−CD122+ CD44+ CD3+ CD8+ T cells were calculated from total CD8+ T cells, 
**p = 0.0023. (B) NK1.1−NKG2D+ CD44+ CD3+ CD8+ T cells were gated from total CD8+ T-cell population in 
day 30 tumor-cell suspensions. Percent NKG2D+ CD44+ CD3+ CD8+ T cells were calculated from total CD8+ 
T cells, **p = 0.0067. (C) CD122+ IFNγ + cells were gated from CD8+ NKG2D+ T cells. Percent was calculated 
from total CD8+ NKG2D+ T cells, ****p < 0.0001. (D) CD25+ CTLA4+ T cells were gated from total CD4+ 
T-cell population within day 30 tumors from wt or Cbx3/HP1γ +/− mice. Percent CD25+ CTLA4+ T cells were 
calculated from total CD4+ T cell-population, ****p < 0.0001. (E) CD25+ FOXP3+ cells were gated from CD4+ 
T cells. Percent was calculated from total CD4+ T-cell population, **p = 0.003. (F) Ctla4 and Foxp3 mRNA 
expression was detected by RT-qPCR in day 30 tumors (4 tumors from each mouse strain). Results represented 
fold difference; unit 1 indicated no change. Each symbol represented an individual mouse; bars represented 
group median. Statistical analysis was performed with the GraphPad unpaired student t-test.
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(Fig. 3C). The frequency of CD25+ CD4+ T cells expressing the inhibitory receptor CTLA4 was ∼ 2.6-fold lower 
in tumors from Cbx3/HP1γ -insufficient mice (Fig. 3D). Additionally, there was a ∼ 3-fold decrease in the fre-
quency and number of CD25+ CD4+ FOXP3+ T cells (Fig. 3E and S3) as well as a reduction in Foxp3 and Ctla4 
expression (Fig. 3F). It is plausible that NK and NKT cells, known to also participate in tumor clearance21,36, 
might have caused tumor growth reduction seen in our Cbx3/HP1γ -insufficient mice. However, we observed no 
differences in the frequency of NKT or Klrk1/NKG2D+ NKT cells in tumors from wt or Cbx3/HP1γ -insufficient 
mice (Fig. S4A,B). No discernable differences were observed in the frequency of tumor-infiltrating CTLA4+ 
CD8+ T cells from either wt or Cbx3/HP1γ -insufficient mice (Fig. S4C). Similar frequency of tumor-infiltrating 
ICOS+ CD4+ and ICOS+ CD8+ T cells was recovered from wt and Cbx3/HP1γ -insufficient mice (Fig. S4D). 
Tumor-infiltrating NK cells were not detected in tumors from either wt or Cbx3/HP1γ -insufficient mice 
(Fig. S4E). Tumors from wt and Cbx3/HP1γ -insufficient mice contained similar frequency of CD80+ and 
CD86+ cells (Fig. S4F). Relatively little differences were observed for other immune cells including B220+ B 
cells, Gr1+ and Mac-1+ myeloid cells in tumors from wt and Cbx3/HP1γ -insufficient mice (Fig. S4G,H). Cbx3/
HP1γ -insufficient CD4+ T cells did not have the propensity to adopt a TH1 phenotype under non-polarizing 
condition (Fig. S4I). Moreover, Cbx3/HP1γ insufficiency did not affect the generation of natural CD4+ Treg cells 
in tumor bearing mice (Fig. S4J). Together, these results show that in tumors from Cbx3/HP1γ -insufficient mice 
there is an increase in CD8+ effector T cells and a decrease of CD4+ Treg cells as well as CD4+ CD25+ CTLA4+ 
T cells.
Adoptive transfer of Cbx3/HP1γ-insufficient CD8+ effector T cells inhibits tumor growth in 
mice. To formally demonstrate that CD8+ T cells cause inhibition of tumor growth, adoptive transfer experi-
ments were performed. NB-9464 tumor cells were implanted in wt mice, on day 12 or 14 after implantation, mice 
were treated with in vitro-activated wt or Cbx3/HP1γ -insufficient CD8+ T cells, and tumor growth was monitored 
until day 31. Treatment of wt tumor-bearing mice with Cbx3/HP1γ -insufficient CD8+ activated T cells alone was 
successful in inhibiting NB tumor growth (Fig. 4A). By contrast, tumor growth continued in mice treated with 
wt CD8+ effector T cells. Analyses of TILs recovered from treated mice revealed 2-fold more CD122+ CD44+ 
CD8+ effector T cells in tumors from mice treated with Cbx3/HP1γ -insufficient CD8+ effector T cells compared 
to those treated with wt cells (Fig. 4B). Similarly, a higher frequency (3.8-fold more) of Klrk1/NKG2D+ CD8+ 
T cells were present in tumors from mice treated with Cbx3/HP1γ -insufficient CD8+ T cells than those treated 
with wt cells (Fig. 4C). There was a significant reduction (4-fold less) in the frequency of CD4+ CD25+ CTLA4+ 
T cells and Foxp3 expression in tumors obtained from mice treated with Cbx3/HP1γ -insufficient CD8+ T cells 
compared to those treated with wt cells (Fig. 4D,E). Expression of Pd-l1 in tumors from mice treated with wt or 
Cbx3/HP1γ -insufficient CD8+ effector T cells remained similar (Fig. 4E). We observed no obvious differences in 
the frequency of other immune cells (Fig. S5A–C). Our results show that treatment with Cbx3/HP1γ -insufficient 
CD8+ effector T cells alone was sufficient to limit tumor growth in wt tumor-bearing mice.
Cbx3/HP1γ occupies Prf1, Gzmb and Ifng loci and in part modulates histone H3K9me3 
deposition. It is not known if and how Cbx3/HP1γ controls CD8+ T-cell effector programming. To objec-
tively address these questions, Chromatin Immunoprecipitation followed by deep Sequencing (ChIP-Seq) was 
performed using chromatin from in vitro-activated wt CD8+ T cells. Cbx3/HP1γ was distributed across the entire 
genome of activated mouse CD8+ T cells with less occupancy at 3′ -UTRs and downstream regions compared to 
ChIP-Seq profile of an unrelated control antibody (Table S1 and Fig. S6). Among genes occupied by Cbx3/HP1γ 
were Prf1, Gzmb and Ifng, and ChIP-qPCR analyses validated Cbx3/HP1γ occupancy at these loci (Fig. 5A,B). 
Cbx3/HP1γ was recruited mainly to the − 2, − 1 kb 5′ upstream and transcription start site (TSS) regions of Prf1, 
while it associated predominantly with the − 7, − 6 kb 5′ upstream, TSS and + 2 kb regions of Gzmb. Cbx3/HP1γ 
occupancy of Ifng locus could only be confirmed at the TSS site. By contrast, in insufficient CD8+ effector T cells, 
Cbx3/HP1γ recruitment to corresponding regions was significantly reduced (> 2 fold reduction). Although Bcl6, 
Prdm1, Tbx21 and Eomes expression in Cbx3/HP1γ -insufficient CD8+ T cells was modified, we observed no dis-
tinct Cbx3/HP1γ -bound peaks within these loci (Fig. S7A–D).
Because Cbx3/HP1γ has been shown to interact with H3K9me3, we asked if diminished Cbx3/HP1γ levels 
would lead to decreased histones H3K9me3 deposition at these loci. Indeed, less H3K9m3 was positioned at 
sites where there was reduced Cbx3/HP1γ occupancy, specifically at 5’ upstream regions and within the gene 
body of Prf1 and Gzmb in Cbx3/HP1γ -insufficient CD8+ effector T cells compared to control cells (Fig. 5C). 
H3K9me3 deposition at Prf1 and Gzmb TSS and + 2 region of the latter was not readily detectable. In Cbx3/
HP1γ -insufficient CD8+ effector T cells, positioning of H3K9m3 was decreased around Ifng TSS region, coin-
ciding with reduced Cbx3/HP1γ occupancy. These results demonstrate that the degree of histones H3K9me3 
deposition at Prf1, Gzmb and Ifng loci correlates, in part, with Cbx3/HP1γ occupancy.
Runx3 occupancy and RNA Polymerase II (Pol II) recruitment/activation to Prf1, Ifng and Gzmb 
are regulated in part by Cbx3/HP1γ. We have previously shown that Runx3 together with Pol II in part 
regulate Prf1, Ifng and Gzmb expression in CD8+ effector T cells19,20. Here, ChIP-qPCR analyses showed that 
in Cbx3/HP1γ -insufficient CD8+ effector T cells, more Runx3 was deposited at sites where Cbx3/HP1γ and 
H3K9me3 occupancy was diminished (Fig. S8A). Additionally, more total Pol II was recruited to Prf1 and Ifng 
TSS regions and at the − 7, − 6 kb 5′ upstream and + 2 kb regions of Gzmb in Cbx3/HP1γ -insufficient CD8+ effec-
tor T cells compared to controls (Fig. S8B). Next we asked if Cbx3/HP1γ regulates Pol II initiation [Pol (S5)]37 and 
elongation [Pol II (S2)]38 phases as well. ChIP-qPCR results demonstrated that the presence of Pol II (S5) at Prf1, 
Gzmb and Ifng loci was augmented (Fig. S8C). Specifically, more Pol II (S5) was bound at the+ 1 and+ 4 regions 
of Prf1 in Cbx3/HP1γ -insufficient CD8+ effector T cells. In Cbx3/HP1γ -insufficient CD8+ effector T cells, more 
Pol II (S5) occupied the − 7 kb 5′ upstream and + 2 kb regions of Gzmb, respectively; the binding pattern of Pol II 
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(S5) and total Pol II was similar. There was also an increased in the level of Pol II (S5) assembled at the TSS region 
of Ifng in Cbx3/HP1γ -insufficient CD8+ effector T cells compared to control cells. There was a small increase in 
Pol II (S2) bound at all three loci in Cbx3/HP1γ -insufficient CD8+ effector T cells (Fig. S8D). These results show 
that more total and initiating/elongating Pol II are recruited to and assembled at Prf1, Gzmb and Ifng in Cbx3/
HP1γ -insufficient CD8+ effector T cells.
Figure 4. Adoptive transfer of Cbx3/HP1γ-insufficient CD8+ effector T cells inhibits tumor growth in 
mice. (A) On day 14 after induction, wt tumor-bearing mice were treated with wt or Cbx3/HP1γ -insufficient 
CD8+ effector T cells. Tumor volume was measured on day 22 after tumor induction (day 8 after treatment) 
until day 31 (n = 8 per treatment group). (B) NK1.1−CD122+ CD44+ CD3+ CD8+ T cells were gated from total 
CD8+ T-cell population in day 31 tumor-cell suspensions of treated mice. Percent NK1.1−CD122+ CD44+ 
CD3+ CD8+ T cells were calculated from total CD8+ T cells, *p = 0.0104. (C) NK1.1−NKG2D+ CD44+ CD3+ 
CD8+ T cells were gated from total CD8+ T-cell population in day 31 tumor-cell suspensions of treated mice. 
Percent NKG2D+ CD44+ CD3+ CD8+ T cells were calculated from total CD8+ T cells, *p = 0.0373. (D) CD25+ 
CTLA4+ T cells were gated from total CD4+ T-cell population within day 31 tumors of treated mice. Percent 
CD25+ CTLA4+ T cells were calculated from total CD4+ T cell-population, ***p = 0.0007. (E) Foxp3 and PD-L1 
mRNA expression was assessed by RT-qPCR in day 31 tumors obtained from treated mice (3 tumors from each 
treatment group). Fold difference was calculated, and the unit 1 indicated no change in expression levels. Each 
symbol represented an individual mouse; bars represented group median. Statistical analysis was performed 
with GraphPad unpaired student t-test.
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Discussion
Here, we reveal a previously unknown and essential role for Cbx3/HP1γ in the control of tumor immunity. We 
show that Cbx3/HP1γ insufficiency releases the effector capacity of CD8+ T cells to control tumor growth in vivo. 
Under Cbx3/HP1γ insufficient condition, chromatin remodeling occurs allowing increased Runx3 and active 
Pol II occupancy that in part could induce Prf1, Gzmb and Ifng expression. Together, these changes may have 
provided the anti-tumor immunity observed in our mouse model.
Cbx3/HP1γ function is diverse. It associates with both heterochromatin and euchromatin suggesting that it 
may participate in transcriptional repression and activation, respectively7,8. However, it is not understood what 
cellular conditions invoke the repressor or activator function to control gene expression. Our results demonstrate 
that in activated CD8+ T cells, Cbx3/HP1γ appears to act as a repressor of the activation-induced genes Prf1, 
Gzmb and Infg. We propose that in normal CD8+ T cells, Cbx3/HP1γ may interact with existing H3K9me3 to 
maintain an unfavorable chromatin structure that limits Runx3 invasion and Pol II recruitment/activation to pre-
vent Prf1, Gzmb and Infg excessive expression. Because Cbx3/HP1γ occupancy does not completely correspond 
with H3K9me3 deposition at TSS of Prf1 and Gzmb or + 2 site of the latter, our data implies that Cbx3/HP1γ may 
interact with another protein(s) yet to be identified in CD8+ T cells. Additionally, we cannot rule out that Cbx3/
HP1γ control unknown genes, which may affect Prf1, Gzmb and Infg expression.
The presence of CD8+ TEX cells has been detected in a number of tumors nonetheless their effector capacity 
can be reinvigorated17. It is not clear if Cbx3/HP1γ -insufficient CD8+ tumor T cells are reinvigorated TEX cells. The 
Figure 5. Cbx3/HP1γ occupies Prf1, Gzmb and Ifng loci and modulates histone H3K9me3 deposition. 
(A) ChIP-Seq was performed using chromatin from activated wt CD8+ T cells. Read-density tracks of Cbx3/
HP1γ ChIP-Seq peaks across Prf1, Gzmb and Ifng were in black. The y-axis represented the number of reads 
per million mapped per 25-bp window; x-axis marked genomic locations. (B) The recruitment of Cbx3/HP1γ 
to Prf1, Gzmb and Ifng loci was confirmed by ChIP-qPCR, *p = 0.0181, **p = 0.0056 (−1kb) and 0.0062 (tss), 
***p = 0.0001, ****p < 0.0001. (C) Histone H3K9me3 deposition on Prf1, Gzmb and Ifng loci was assessed, 
*p = 0.0271, **p = 0.0011, ****p < 0.0001. All ChIP-qPCR results were representative of 4–5 independent ChIPs. 
TSS: transcription start site, numbers on x-axis indicated positions of primers (in kb) along Prf1 and Gzmb loci, 
and 150 bp products were amplified using specific primers. Statistical analysis was performed with GraphPad 
unpaired student t-test and One-Way Anova.
www.nature.com/scientificreports/
9Scientific RepoRts | 7:42888 | DOI: 10.1038/srep42888
fact that more CD8+ T cells with effector characteristics are recovered from tumors of Cbx3/HP1γ -insufficient 
mice suggests that Cbx3/HP1γ insufficiency can reinvigorate the effector capacity of CD8+ T cells to control 
tumor growth. However, it is not yet known how Cbx3/HP1γ does so.
It is not yet understood why CD4+ Treg cells and CTLA4+CD25+CD4+ T cells are reduced. It is plausible that 
Cbx3/HP1γ -insufficient CD8+ effector T cells may alter the tumor microenvironment thus preventing CD4+ Treg 
infiltration39. Alternatively, Cbx3/HP1γ -insufficient CD8+ effector T cells may control CD4+ Treg numbers in 
tumors or Cbx3/HP1γ may directly control CD4+ Treg differentiation/function.
Several forms of immunotherapies are being used in the clinic with objective clinical responses. Here, we 
reveal an alternative novel strategy to boost tumor immunity. By reducing the levels of Cbx3/HP1γ we can 
increase CD8+ effector T cells at the same time eliminate CD4+ Treg immune suppression in the tumor microen-
vironment that may control tumor growth.
Methods
Mice and cell lines. Cbx3/HP1γ -deficient mice were generated, as described13. These mice were backcrossed 
to C57BL/6 for twelve generations. B6-Rag2−/−Cγ−/− mice were purchased from Taconic. When needed, female 
8–12 weeks old C57BL/6 mice were purchased from The Jackson Laboratory. All mice were maintained in spe-
cific pathogen-free conditions. All mouse protocols were approved by the BIDMC Institutional Animal Care and 
Use Committee. All experiments were performed in accordance with relevant guidelines and regulations. The 
NB-9464 neuroblastoma cell line was a kind gift from Dr. Crystal MacKall at Stanford University.
Antibodies. All flow cytometry fluorochrome-conjugated antibodies were purchased from Biolegend, eBio-
sciences or BD Biosciences. All other antibodies were purchased as followed: anti-mouse total and phosphoryl-
ated Cbx3/HP1γ (Cell Signaling); anti-mouse RAE-1 pan-specific (R&D Systems); anti-mouse granzyme B (clone 
16G6, eBiosciences); anti-mouse Eomes (Abcam); anti-mouse T-bet (clone 4B10, BioLegend); anti-mouse cleaved 
caspase 3 (Cell Signaling).
Tumor induction. Cbx3/HP1γ +/− and wild-type littermate mice were implanted subcutaneously with 
NB-9464 (1 × 106/mouse) tumor cells in 100 μ l PBS. NB-9464 tumor volume was measured and calculated 
(W × L × 0.4) on day 22 and every 2 days until day 30 or 36 depending on the size of the tumor, at which time 
mice were sacrificed for analysis.
Fetal liver chimeras. At 17.5 days post coitum (d.p.c), pregnant female mice were euthanized and fetuses 
were retrieved. Genotyping of fetuses were performed. Fetal livers from fetuses of the correct genotype were 
dissected. Fetal liver cell suspension was prepared by passing through a 40 μ m cell strainer and a 3-ml syringe 
in cold medium. Fetal liver cells were washed and resuspended at 1 × 107/ml in cold PBS. 200 μ l of fetal liver cell 
suspension was injected intravenously into 7 week-old Rag2−/−Cγ−/− recipients. Ten weeks after reconstitution, 
chimeric mice were implanted subcutaneously with 1 × 106 NB-9464 tumor cells in 100 μ l PBS. Tumor volume 
was measured and calculated (W × L × 0.4) on day 21 and every 2 days until day 29, at which time mice were 
sacrificed for analysis. Control wt fetal livers were obtained from littermate fetuses.
Adoptive T-cell therapy (ACT). In vitro-generated CD8+ effector T cells were prepared as above. On day 0, 
female C57BL/6 mice were implanted subcutaneously with NB-9464 (1 × 106/mouse) tumor cells in 100 μ l PBS. 
On day 14 after tumor induction, mice were treated with 3 × 106 CD8+ effector T cells via intravenous injection. 
NB-9464 tumor volume was measured and calculated (W × L × 0.4) on day 22 until day 31, at which time mice 
were sacrificed for analysis.
Fluorescence-activated cell sorting or flow cytometry (FACS). FACS was performed on the BD 
5-laser LSR II. Analysis was performed with FlowJo software (Tree Star, Inc.). Tumor cells and tumor infiltrating 
lymphocytes were prepared from NB-9464 tumors 29 or 30 days after implantation. Tumors were harvested, 
minced, and cell suspension was filtered through a 70 μ m cell strainer (Falcon). Cells were washed and stained 
for appropriate surface markers as indicated in figures. Intracellular IFNγ staining was performed according to 
manufacturer’s protocol (Affymetrix/eBioscience). Briefly, activated or intratumoral CD8+ T cells (1 × 106) were 
treated with 1X cell stimulation cocktail with protein transport inhibitors (Affymetrix/eBioscience) in complete 
T-cell medium for 4 hrs at 37 °C. Cells were harvested and washed 2X with FACS buffer [PBS, 2% fetal bovine 
serum (FBS)]. Standard surface staining was performed. Cells were washed and incubated in fixation/permeabili-
zation buffer (Affymetrix/eBioscience) for 30 minutes at room temperature (RT) or 18 hrs at 4 °C. Following incu-
bation, cells were washed 2X with permeabilization buffer (Affymetrix/eBioscience) and stained for IFNγ using 
fluorochrome-antibodies. Cells were incubated for 30 minutes at RT. Cells were washed 2X with permeabilization 
buffer and resuspended in FACS buffer for analysis. Intracellular FOXP3 staining of intratumoral CD4+ CD25+ T 
cells was performed using similar protocol but without activation with stimulation cocktail.
In vitro activation and differentiation of CD8+ T cells to generate effector cells. CD8+ CD44− T 
cells were purified from spleen and peripheral lymph nodes using mouse CD8 FlowComp dynabeads accord-
ing manufacturer’s protocol (Life Technologies/Thermo Fisher Scientific). T cells (1 × 106/ml) were activated 
with plate-bound anti-CD3 (clone 145-2C11, 0.25 μ g/ml, BioLegend) and anti-CD28 (clone 37.51, 0.5 μ g/ml, 
BioLegend) in T-cell medium (DMEM, 10% FBS, P/S, non-essential amino acids, HEPES, L-glutamate and 
sodium pyruvate) at 37 °C in 10% CO2 for 2 days. Cells were removed from CD3/CD28 activation and recultured 
(5 × 105/ml) in T-cell medium supplemented with IL-2 (10 U/ml or 100 U/ml) at 37 °C in 10% CO2. Cells were 
subcultured everyday. On day 5, cells were harvested and used for analyses or adoptive T-cell therapy.
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Co-cultures of effector cells with NB-9464 tumor cell line for apoptosis induction. Target 
NB-9464 tumor cells were plated in 12-well plates at a density of 5 × 105 cells per well in 750 μ l of RPMI with 10% 
fetal bovine serum (FBS). Activated CD8+ or CD4+ T cells were added. For ratio of 1:1 (effector:target), 5 × 105 
CD8+ or CD4+ T cells: 5 × 105 NB-9464 cells were co-cultured in the same well; ratio 5:1, 2.5 × 106 CD8+ or 
CD4+ T cells: 5 × 105 NB-9464 cells. Plates were incubated at 37 °C in 5% CO2 for 24 hours. Wells were washed to 
remove non-adherent T cells. Adherent NB-9464 cells were collected and washed with 1 ml cold PBS.
Histology and immunohistochemistry. Hematoxylin and eosin (H&E) staining and immunohistochem-
istry were performed using 4 μ m thick formalin-fixed, paraffin-embedded tissue sections. Briefly, slides were 
soaked in xylene, passed through graded alcohols and put in distilled water. Slides were then pre-treated with 
1.0-mM EDTA, pH 8.0 or 1.0 mM Citrate (Zymed) in a steam pressure cooker (Decloaking Chamber, BioCare 
Medical) as per manufacturer’s instructions, followed by washing in distilled water. All subsequent steps were per-
formed at room temperature in a hydrated chamber. Slides were pre-treated with Peroxidase Block (DAKO) for 
5 minutes to quench endogenous peroxidase activity, followed by Serum free Protein Block (DAKO) for 20 min-
utes. Rabbit monoclonal antibody against mouse KI-67 (clone D3B5, Cell Signaling Technology) was applied and 
slides were incubated overnight at 4 °C. Slides were washed 2X in 50 mM Tris-Cl, pH 7.4 then followed with goat 
anti-rabbit IgG-HRP (SouthernBiotech), and incubated for 15 minutes. After further washing, immunoperox-
idase staining was developed using a DAB chromogen (DAKO) and counterstained with hematoxylin. Images 
were acquired with the Nikon Eclipse TE2000 and were captured with the Hamamatsu Orca ER digital CCD 
camera and analyzed with NIS elements 4.13 software. Images were shown as 100X (10X ocular and 10X objective 
lens) and 400X (10X ocular and 40X objective lens).
Western blots. Cells (1 × 106) cells were lysed with Radio-Immunoprecipitation Assay (RIPA) buffer 
(Boston BioProducts) containing protease inhibitor cocktail (Roche) on ice for 30 minutes. Cells were centri-
fuged at 14,000 rpm for 15 minutes at 4 °C. Protein concentration was determined by Bio-Rad Protein Assay Kit 
(BioRad). 10 μ g of protein extracts were denatured at 95 °C for 10 minutes, separated by SDS-PAGE, and trans-
ferred onto PVDF membranes (EMD Millipore). Membranes were probed with antibodies. Proteins of interest 
were detected with HRP-conjugated secondary antibodies and visualized with the Pierce ECL Western blotting 
substrate (Thermo Fisher Scientific). Membranes were exposed with HyBlot CL Autoradiography films (Denville 
Scientific, Inc.), and developed with the Kodax X-OMAT 2000 Processor. Films were scanned with the Epson 
XP-610 scanner using black and white setting, and images were captured by Adobe Photoshop Elements Editor.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The Bio-Rad Hard-Shell 
PCR Plates (BioRad) were used. In each well, 2.5 μ l of sample was added in triplicates along with 7.5 μ l of the primer 
mixture, which consisted of 0.5 μ l forward primer, 0.5 μ l reverse primer, 1.7 μ l PCR grade water, and 5 μ l of Roche 
LightCycler 480 SYBR Green I Master (Roche). The plate was centrifuged at 300 RCF for 1 minute and read in the 
Bio-Rad CFX384 Real-Time System (BioRad). The qPCR settings were as follow: 95 °C for 10:00 minutes 95 °C 
for 0:10 minutes, 62 °C for 0:20 minutes, 72 °C for 0:20 minutes (Read Plate), GOTO step 2 for 39 times, 92 °C for 
0:05 minutes, Melt Curve 65.0 °C to 97.0 °C at increment 0.5 °C for 1:00 minutes (Read Plate), 40 °C for 0:10 minutes.
Chromatin immunoprecipitation (ChIP). The chromatin immunoprecipitation (ChIP) was performed using 
the MAGnify ChIP System according to manufacturer’s protocol with minor modifications to optimize the assay 
(Life Technologies). Briefly, 2 × 107 CD8+ T cells were used for each ChIP experiment. The volume of Dynabeads 
Protein A/G, DNA Purification Magnetic Beads, and all the buffers were decreased by half of the suggested amount. 
Cells were lysed with 500 μ l of lysis buffer containing 1X protease inhibitors and incubated on ice for 20 minutes. 
Chromatin was sheared using a Sonic Dismembrator (Fisher Scientific Model 120) at 50% power, at 10 seconds per 
cycle, for 7 cycles. The sheared chromatin was added to the Antibody-Dynabeads complex and incubated overnight 
at 4 °C in a rotating shaker for maximum binding. The heat source used was the Thermal Cycler from Bio-Rad (model 
C1000). The DNA was eluted using 80 μ l of elution buffer, and the purified DNA was immediately used for qPCR.
ChIP followed by deep sequencing (ChIP-Seq). Chromatin Immunoprecipitation. Mouse 
day-5-activated T cells were fixed with 1% formaldehyde for 15 min and quenched with 0.125 M glycine. 
Chromatin was isolated by the addition of lysis buffer and disruption with a Dounce homogenizer. Lysates were 
sonicated and the DNA sheared to an average length of 300–500 bp. Genomic DNA (Input) was prepared by 
treating aliquots of chromatin with RNase, proteinase K and heat for de-crosslinking, followed by ethanol pre-
cipitation. Pellets were resuspended and the resulting DNA was quantified on a NanoDrop spectrophotometer. 
Extrapolation to the original chromatin volume allowed quantitation of the total chromatin yield. An aliquot of 
chromatin (30 μ g) was precleared with protein G agarose beads (Invitrogen). Genomic DNA regions of interest 
were isolated using cbx3+/−/HP1γ antibody (Cell Signaling). Complexes were washed, eluted from the beads with 
SDS buffer, and subjected to RNase and proteinase K treatment. Crosslinks were reversed by incubation overnight 
at 65 °C, and ChIP DNA was purified by phenol-chloroform extraction and ethanol precipitation.
ChIP Sequencing (Illumina). Illumina sequencing libraries were prepared from the ChIP and Input DNAs by 
the standard consecutive enzymatic steps of end-polishing, dA-addition, and adaptor ligation. After a final PCR 
amplification step, the resulting DNA libraries were quantified and sequenced on HiSeq 2500. Sequences (50 nt 
reads, single end) were aligned to the mouse genome (mm10) using the BWA algorithm. Aligns were extended 
in silico at their 3′ -ends to a length of 200 bp, which is the average genomic fragment length in the size-selected 
library, and assigned to 32-nt bins along the genome. The resulting histograms (genomic “signal maps”) were 
stored in BigWig files. Details of data analysis are shown in Supplementary Information.
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